Efficacy and safety of neratinib and capecitabine in HER2 positive metastatic breast cancer: a systematic review

被引：0
|
作者：
Mokalu, E. Wilhelmina [1 ]
Sabran, M. Zuhriansyah [1 ]
Yossy, P. [1 ]
Rubismo, K. Yogasvara [1 ]
Zebua, A. [1 ]
Albert, N. [1 ]
Hasan, J. Irisha Xenia [1 ]
Kurniawan, A. [2 ]
机构：
[1] Univ Pelita Harapan, Fac Med, Tangerang, Indonesia
[2] Univ Pelita Harapan, Dept Internal Med, Fac Med, Tangerang, Indonesia
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.07.472
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P90-6
引用
收藏
页码：S1393 / S1393
页数：1
相关论文
共 50 条
  • [41] Incorporating Neratinib Into Clinical Practice for Patients With HER2-Positive Metastatic Breast Cancer
    Isaacs, Claudine
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 12 - 15
  • [42] Systemic treatment of HER2-positive metastatic breast cancer: A systematic review
    Wilcken, Nicholas
    Zdenkowski, Nicholas
    White, Michelle
    Snyder, Ray
    Pittman, Ken
    Mainwaring, Paul
    Green, Michael
    Francis, Prudence
    De Boer, Richard
    Colosimo, Maree
    Chua, Sue
    Chirgwin, Jacquie
    Beith, Jane
    Bell, Richard
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 1 - 14
  • [43] HER2 positive breast cancer
    Gianni, Luca
    Bianchini, Giampaolo
    CANCER RESEARCH, 2023, 83 (05)
  • [44] Neratinib in HER2-Positive Breast Cancer Patients
    Paranjpe, Rutugandha
    Basatneh, Dima
    Tao, Gabriel
    De Angelis, Carmine
    Noormohammed, Sobia
    Ekinci, Ekim
    Abughosh, Susan
    Ghose, Romi
    Trivedi, Meghana V.
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (06) : 612 - 620
  • [45] Phase Ib/II study of capecitabine 7/7 schedule with neratinib in patients with HER2-positive metastatic breast cancer (MBC).
    Wang, Rui
    Singh, Jasmeet Chadha
    Wong, Serena Tsan-Lai
    Lake, Diana
    Iyengar, Neil M.
    D'Andrea, Gabriella
    Brockway-Marchello, Julia P.
    Kaba, Asta
    Traina, Tiffany A.
    Robson, Mark E.
    Dang, Chau T.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] Phase Ib/II study of capecitabine 7/7 schedule with neratinib in patients with HER2-positive metastatic breast cancer (MBC)
    Wang, R.
    Singh, J.
    Sterlin, V.
    Goldstein, M.
    Lake, D.
    Wong, S.
    Baselga, J.
    Norton, L.
    Dang, C.
    CANCER RESEARCH, 2019, 79 (04)
  • [47] Neratinib (Nerlynx) for HER2-Positive Breast Cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2018, 60 (1539): : 23 - 23
  • [48] Predictive significance of the mucocutaneous toxicities, but not dose intensity of capecitabine for the treatment of lapatinib plus capecitabine in patients with HER2 positive metastatic breast cancer
    Araki, K.
    Fukada, I.
    Takahashi, S.
    Ito, Y.
    CANCER RESEARCH, 2013, 73
  • [49] Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial
    He, Maiyue
    Liu, Jiaxuan
    Wang, Zijing
    Ma, Fei
    Wang, Jiayu
    Zhang, Pin
    Li, Qing
    Yuan, Peng
    Luo, Yang
    Fan, Ying
    Mo, Hongnan
    Lan, Bo
    Li, Qiao
    Xu, Binghe
    BREAST, 2023, 72
  • [50] Safety and efficacy study of oral metronomic capecitabine in combination with pyrotinib for HER2-positive metastatic breast cancer: A phase II trial
    Li, Qiao
    He, Maiyue
    Liu, Jiaxuan
    Wang, Zijing
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345